Terms: = Prostate cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Clinical Outcome
12 results:
1. A concise review on the role of BDNF-AS in human disorders.
Ghafouri-Fard S; Khoshbakht T; Taheri M; Ghanbari M
Biomed Pharmacother; 2021 Oct; 142():112051. PubMed ID: 34426254
[TBL] [Abstract] [Full Text] [Related]
2. The PTEN Conundrum: How to Target PTEN-Deficient prostate cancer.
Turnham DJ; Bullock N; Dass MS; Staffurth JN; Pearson HB
Cells; 2020 Oct; 9(11):. PubMed ID: 33105713
[TBL] [Abstract] [Full Text] [Related]
3. Valproic Acid Addresses Neuroendocrine Differentiation of LNCaP Cells and Maintains Cell Survival.
Giordano F; Naimo GD; Nigro A; Romeo F; Paolì A; De Amicis F; Vivacqua A; Morelli C; Mauro L; Panno ML
Drug Des Devel Ther; 2019; 13():4265-4274. PubMed ID: 31908413
[TBL] [Abstract] [Full Text] [Related]
4. The Evolutionary Landscape of Localized prostate cancers Drives clinical Aggression.
Espiritu SMG; Liu LY; Rubanova Y; Bhandari V; Holgersen EM; Szyca LM; Fox NS; Chua MLK; Yamaguchi TN; Heisler LE; Livingstone J; Wintersinger J; Yousif F; Lalonde E; Rouette A; Salcedo A; Houlahan KE; Li CH; Huang V; Fraser M; van der Kwast T; Morris QD; Bristow RG; Boutros PC
Cell; 2018 May; 173(4):1003-1013.e15. PubMed ID: 29681457
[TBL] [Abstract] [Full Text] [Related]
5. MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mtor signaling.
Offermann A; Vlasic I; Syring I; Vogel W; Ruiz C; Zellweger T; Rentsch CA; Hagedorn S; Behrends J; Nowak M; Merseburger A; Bubendorf L; Kirfel J; Duensing S; Adler D; Perner S
Oncotarget; 2017 Jan; 8(5):7964-7976. PubMed ID: 27974704
[TBL] [Abstract] [Full Text] [Related]
6. The cannabinoid WIN 55,212-2 prevents neuroendocrine differentiation of LNCaP prostate cancer cells.
Morell C; Bort A; Vara D; Ramos-Torres A; Rodríguez-Henche N; Díaz-Laviada I
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):248-57. PubMed ID: 27324222
[TBL] [Abstract] [Full Text] [Related]
7. [The mechanism of progression without androgen receptor interaction in prostate cancer].
Matsuyama H; Matsumoto H
Nihon Rinsho; 2016 Jan; 74(1):60-5. PubMed ID: 26793881
[TBL] [Abstract] [Full Text] [Related]
8. Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant prostate cancer Pretreated With Docetaxel Chemotherapy: A prostate cancer clinical Trial Consortium Study.
Vaishampayan U; Shevrin D; Stein M; Heilbrun L; Land S; Stark K; Li J; Dickow B; Heath E; Smith D; Fontana J
Urology; 2015 Dec; 86(6):1206-11. PubMed ID: 26375845
[TBL] [Abstract] [Full Text] [Related]
9. mtor is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer.
Schiewer MJ; Den R; Hoang DT; Augello MA; Lawrence YR; Dicker AP; Knudsen KE
Endocr Relat Cancer; 2012 Feb; 19(1):1-12. PubMed ID: 21903859
[TBL] [Abstract] [Full Text] [Related]
10. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.
Minner S; Enodien M; Sirma H; Luebke AM; Krohn A; Mayer PS; Simon R; Tennstedt P; Müller J; Scholz L; Brase JC; Liu AY; Schlüter H; Pantel K; Schumacher U; Bokemeyer C; Steuber T; Graefen M; Sauter G; Schlomm T
Clin Cancer Res; 2011 Sep; 17(18):5878-88. PubMed ID: 21791629
[TBL] [Abstract] [Full Text] [Related]
11. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer.
Sircar K; Yoshimoto M; Monzon FA; Koumakpayi IH; Katz RL; Khanna A; Alvarez K; Chen G; Darnel AD; Aprikian AG; Saad F; Bismar TA; Squire JA
J Pathol; 2009 Aug; 218(4):505-13. PubMed ID: 19402094
[TBL] [Abstract] [Full Text] [Related]
12. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
[TBL] [Abstract] [Full Text] [Related]
